New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics in U.S. District Court for the ...

A series of case reports to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept), describe how a technology giving insulin doses ...

New features, especially with regard to lead design and geometry, characterize the system. Specifically Medtronic redesigned ... of reed-switch to a Hall sensor. Furthermore, it has developed ...

Meanwhile, Boston Scientific is still waiting for antitrust regulators to conclude their review of its proposal to buy Axonics, which was announced in January.

Advanced materials are key to next-gen sensors, improving sensitivity and durability for critical applications in healthcare ...

MDT stock breaking above its 200 and 50-day SMAs can be a piece of good news for investors, signaling an uptrend.

New vice president of clinical affairs and board of directors member will support advancement of eLym System therapy for acute decompensated heart failure WhiteSwell, a company pioneering a new ...

After nearly a decade of development, the Apple Watch is being leveraged on an entirely new health frontier: Parkinson’s ...

The Continuous Glucose Monitoring Market is Growing at a CAGR of 7.80%, Driven by the Increasing Prevalence of Prediabetes ...

Medtronic has already experienced success with the full market release of its related Simplera Sync sensor internationally, boding well for the U.S. launch of this new CGM. Medtronic will likely ...